MFT
BMY.RT

Moisand Fitzgerald Tamayo’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Moisand Fitzgerald Tamayo’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,222
Closed -$1K – 414
2020
Q4 		$1K Buy
1,222
+13
+1% +$28 ﹤0.01% 349
2020
Q3 		$3K Hold
1,209
– – ﹤0.01% 279
2020
Q2 		$4K Buy
+1,209
New +$4.36K ﹤0.01% 246

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Moisand Fitzgerald Tamayo's BMY.RT Position: Q1 2021 in Review

Moisand Fitzgerald Tamayo sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,222 shares — an estimated $1K sold.

Moisand Fitzgerald Tamayo first reported a position in BMY.RT in Q2 2020 and held it in 3 quarters. The position peaked at $4K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Moisand Fitzgerald Tamayo reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Moisand Fitzgerald Tamayo sold 1,222 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1K.
  • Moisand Fitzgerald Tamayo first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q2 2020 and held it in 3 quarters.
  • Moisand Fitzgerald Tamayo's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $4K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Moisand Fitzgerald Tamayo's 13F filing for Q1 2021, filed 3 May 2021.